Hence, it is possible that a more potent and efficacious Bcl-2/Bcl-xL dual inhibitor may still have a promising therapeutic potential against SCLC tumors with a high expression of Bcl-2 and/or Bcl-xL and a low expression of Mcl-1 as a single agent. The gene discussed is MCL1; the disease is small cell lung carcinoma.